Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
Medtronic concludes CathWorks’ acquisition for $585m
Medtronic has completed the acquisition of CathWorks, a company specialising in advancing the diagnosis and treatment of coronary artery disease …
-
Atsena secures DMC approval for LIGHTHOUSE trial
Atsena Therapeutics is set to proceed with the pivotal Part C cohort of its Phase I/II/III LIGHTHOUSE trial of ATSN-201 …
-
Asahi Kasei acquires German company Aicuris
Asahi Kasei has completed its acquisition of Aicuris Anti-infective Cures, a German biopharmaceutical company. The move comes after Asahi Kasei signed …
-
Bruker unveils MyGenius PRO diagnostics system
The Bruker Microbiology & Infection Diagnostics division has announced the European launch of its MyGenius PRO automated sample-to-answer (S2A) molecular …
-
Agenus announces Phase II results from gastroesophageal cancer therapy
Agenus has reported results from a Phase II trial, evaluating the combination of botensilimab (BOT), balstilimab (BAL), and agenT-797 alongside …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
MSD secures EC approval for Enflonsia to prevent infant RSV infection
Merck & Co (MSD) has received the European Commission (EC) approval for Enflonsia (clesrovimab), indicated to prevent respiratory syncytial virus …
-
Philips secures FDA clearance for Verida spectral CT system
Philips has received 510(k) clearance from the US Food and Drug Administration (FDA) for its Verida system. The device is an …
-
First patient receives JANX014 dose in Janux’s trial for mCRPC
Janux Therapeutics has announced the dosing of its first patient in a Phase I clinical trial evaluating JANX014 for metastatic …
-
Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions
Daiichi Sankyo has signed a research partnership with Interna Therapeutics to develop targeted delivery solutions based on molecular nano motor …
-
Phantom Neuro secures approval for muscle-machine interface trial
Phantom Neuro has secured approval to initiate its first-in-human trial of the Phantom X system, a minimally invasive muscle-machine interface, …
-
Precision receives CTA approval to expand ELIMINATE-B study
Precision BioSciences has received clinical trial application (CTA) approval to expand its global ELIMINATE-B study of PBGENE-HBV, an in vivo …
-
Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study
Boehringer Ingelheim and Zai Lab have entered a clinical collaboration to investigate a dual delta-like ligand 3 (DLL3)-targeting approach for …
-
GlycoNex secures Japan’s PMDA approval for GNX1021 Phase I trial
GlycoNex has received Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) approval to commence a first-in-human Phase I clinical trial of …
-
AIP to acquire Avanos Medical for $1.27bn
US-based Avanos Medical has entered a definitive agreement to be acquired by affiliates of American Industrial Partners (AIP) in an …
-
Lilly to acquire CrossBridge Bio for up to $300m
Eli Lilly and Company has agreed to acquire all outstanding shares of CrossBridge Bio for up to $300m in cash, …
